Kamada Ltd. (KMDA): Price and Financial Metrics
GET POWR RATINGS... FREE!
KMDA Stock Summary
- With a year-over-year growth in debt of 757.22%, Kamada Ltd's debt growth rate surpasses 98.09% of about US stocks.
- In terms of twelve month growth in earnings before interest and taxes, Kamada Ltd is reporting a growth rate of -103.23%; that's higher than merely 17.58% of US stocks.
- Revenue growth over the past 12 months for Kamada Ltd comes in at -22.22%, a number that bests only 6.71% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to Kamada Ltd, a group of peers worth examining would be THTX, AMKR, CRNT, SONM, and SPNS.
- Visit KMDA's SEC page to see the company's official filings. To visit the company's web site, go to www.kamada.com.
KMDA Valuation Summary
- KMDA's EV/EBIT ratio is 13.6; this is 53.58% lower than that of the median Healthcare stock.
- KMDA's EV/EBIT ratio has moved down 70.7 over the prior 100 months.
- Over the past 100 months, KMDA's EV/EBIT ratio has gone down 70.7.
Below are key valuation metrics over time for KMDA.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| KMDA | 2021-08-31 | 2.1 | 1.3 | 19.9 | 13.6 |
| KMDA | 2021-08-30 | 2.1 | 1.3 | 20.0 | 13.7 |
| KMDA | 2021-08-27 | 2.1 | 1.3 | 19.9 | 13.6 |
| KMDA | 2021-08-26 | 2.1 | 1.3 | 19.8 | 13.5 |
| KMDA | 2021-08-25 | 2.1 | 1.3 | 19.9 | 13.6 |
| KMDA | 2021-08-24 | 2.0 | 1.3 | 19.7 | 13.4 |
KMDA Growth Metrics
- The 2 year price growth rate now stands at 49.89%.
- Its 3 year net income to common stockholders growth rate is now at 413.75%.
- The 3 year price growth rate now stands at 48.01%.
The table below shows KMDA's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-12-31 | 103.642 | -8.819 | -2.23 |
| 2021-09-30 | 103.715 | 8.899 | 4.408 |
| 2021-06-30 | 116.006 | 9.189 | 12.088 |
| 2021-03-31 | 124.856 | 23.127 | 14.609 |
| 2020-12-31 | 133.246 | 19.105 | 17.14 |
| 2020-12-31 | 133.246 | 19.105 | 17.14 |
KMDA Price Target
For more insight on analysts targets of KMDA, see our KMDA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $11.00 | Average Broker Recommendation | 1.5 (Moderate Buy) |
KMDA Stock Price Chart Interactive Chart >
KMDA Price/Volume Stats
| Current price | $4.67 | 52-week high | $6.96 |
| Prev. close | $4.63 | 52-week low | $4.48 |
| Day low | $4.60 | Volume | 18,000 |
| Day high | $4.70 | Avg. volume | 25,919 |
| 50-day MA | $5.36 | Dividend yield | N/A |
| 200-day MA | $5.72 | Market Cap | 207.91M |
Kamada Ltd. (KMDA) Company Bio
Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates through two segments, Proprietary Products and Distribution. The company was founded in 1990 and is based in Ness Ziona, Israel.
Latest KMDA News From Around the Web
Below are the latest news stories about Kamada Ltd that investors may wish to consider to help them evaluate KMDA as an investment opportunity.
$23.37 Million in Sales Expected for Kamada Ltd. (NASDAQ:KMDA) This QuarterWall Street brokerages forecast that Kamada Ltd. (NASDAQ:KMDA) will report sales of $23.37 million for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Kamada’s earnings. The lowest sales estimate is $22.24 million and the highest is $24.50 million. Kamada reported sales of $31.54 million during the same quarter last […] |
Analysts Anticipate Kamada Ltd. (NASDAQ:KMDA) to Post $0.02 Earnings Per ShareEquities analysts expect that Kamada Ltd. (NASDAQ:KMDA) will announce $0.02 earnings per share for the current quarter, according to Zacks. Two analysts have issued estimates for Kamadas earnings. The highest EPS estimate is $0.04 and the lowest is ($0.01). Kamada reported earnings of $0.04 per share in the same quarter last year, which suggests a [] |
Analysts Expect Kamada Ltd. (NASDAQ:KMDA) Will Post Quarterly Sales of $23.37 MillionWall Street analysts predict that Kamada Ltd. (NASDAQ:KMDA) will post $23.37 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Kamadas earnings, with estimates ranging from $22.24 million to $24.50 million. Kamada posted sales of $31.54 million during the same quarter last year, which would indicate [] |
Kamada Ltd. (NASDAQ:KMDA) Short Interest Down 21.3% in NovemberKamada Ltd. (NASDAQ:KMDA) saw a significant drop in short interest in the month of November. As of November 15th, there was short interest totalling 546,800 shares, a drop of 21.3% from the October 31st total of 695,200 shares. Based on an average daily volume of 49,200 shares, the days-to-cover ratio is presently 11.1 days. Currently, [] |
Kamada (NASDAQ:KMDA) Downgraded to Sell at Zacks Investment ResearchZacks Investment Research downgraded shares of Kamada (NASDAQ:KMDA) from a hold rating to a sell rating in a research note released on Wednesday, Zacks.com reports. According to Zacks, Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and [] |
KMDA Price Returns
| 1-mo | -15.40% |
| 3-mo | -19.06% |
| 6-mo | N/A |
| 1-year | -22.04% |
| 3-year | -17.78% |
| 5-year | -34.23% |
| YTD | -29.03% |
| 2021 | 1.54% |
| 2020 | -5.12% |
| 2019 | 36.60% |
| 2018 | 5.26% |
| 2017 | -12.84% |
Continue Researching KMDA
Want to see what other sources are saying about Kamada Ltd's financials and stock price? Try the links below:Kamada Ltd (KMDA) Stock Price | Nasdaq
Kamada Ltd (KMDA) Stock Quote, History and News - Yahoo Finance
Kamada Ltd (KMDA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...